SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Shopify, Inc. is a global commerce company that provides essential internet infrastructure for commerce, offering trusted tools to start, scale, market, and run a retail business of any size. The Company's software enables merchants to run their business across all of their sales channels, including web and mobile storefronts, physical retail locations, social media storefronts and marketplaces. The Shopify platform provides merchants with a single view of their business across all of their sales channels and enables them to manage products and inventory, process orders and payments, fulfill and ship orders, build customer relationships, source products, leverage analytics and reporting and access financing, all from one integrated back office. The company was founded on September 28, 2004 and is headquartered in Ottawa, Canada.

Shopify Inc - Ordinary Shares - Class A (Sub Voting)

Shopify Inc

Shopifys sharp selloff after its Q3 report dominates discussion: traders point to softer-than-expected merchandise volume and slower projected gross-profit growth, despite solid profitability and cash generation. Bears say the high valuation left little room for disappointment, while bulls view the reaction as excessive given continued growth.

Upstart Holdings, Inc. engages in the provision of a cloud-based artificial intelligence lending platform. It operates through the following segments: Personal Lending, Auto Lending, and Other. The Personal Lending segment focuses on unsecured personal loans and small dollar loans. The Auto Lending segment is involved in auto refinance and auto retail loans. The Other segment refers to HELOCs and other. The company was founded by David Joseph Girouard, Anna Mongayt Counselman, and Paul Gu in December 2013 and is headquartered in San Mateo, CA.

Upstart Holdings Inc

Upstarts Q3 results have traders debating strong revenue growth and a return to profitability against cautious, lower guidance, which many blame for the selloff. Bulls see improving loan volume and margins as evidence the business is gaining traction, while bears focus on interest-rate, credit-risk and funding concerns.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

Reports that nonprofit Usona may have filed an FDA application for psilocybin in major depressive disorder triggered a sharp selloff and concerns about competition and which company could reach the market first. Traders debate the threat, noting Compass is targeting treatment-resistant depression and has commercial infrastructure, while questioning how confirmed Usonas filing is and watching for Compasss own NDA completion.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

Luckins third-quarter results are drawing attention, with traders welcoming stronger profitability and a new share-repurchase program while debating the revenue shortfall and weak same-store sales. The reaction is split between optimism about margins and expansion and frustration that the stock remains range-bound, with some also noting the lack of relisting guidance.

Aehr Test Systems engages in the design, manufacture, market, and sale of test and burn-in equipment used in the semiconductor industry. Its products include FOX-XP, FOX-NP, and FOX-CP wafer contact parallel test and burn-in systems, the WaferPak full wafer contactor, the DiePak Carrier, the WaferPak Aligner, the DiePak Autoloader, and test fixtures. The company was founded by Rhea J. Posedel on May 25, 1977 and is headquartered in Fremont, CA.

Aehr Test Systems

Aehrs fiscal Q1 results beat expectations, with record revenue, strong bookings and a higher fiscal-year outlook supporting optimism about AI-chip burn-in testing demand. Traders are cheering the growth but debating the stocks rich valuation and whether the gains can hold amid market weakness and AEHRs volatility.

Backblaze, Inc. operates as a cloud provider for businesses and consumers to store, use, and protect their data. The firm provides a foundation for businesses, developers, IT professionals, and individuals to store, backup, and archive data, host content, manage media, and build their applications. It also offers B2 Cloud Storage and Computer Backup services. The company was founded by Timothy Nufire, Gleb Budman, Charles Jones, Kwok Hang Ng, Brian Wilson, Nilay Patel and Damon Uyeda in 2007 and is headquartered in San Francisco, CA.

Backblaze Inc - Ordinary Shares - Class A

Backblazes quarterly results and raised full-year outlook are driving attention, with traders focused on accelerating B2 cloud-storage growth and its potential role in AI infrastructure. The reaction is divided: some see strong execution and improving cash generation, while others flag weaker retention, declining legacy backup revenue and the risk of a sell-the-news pullback.

Fiserv, Inc. engages in the provision of financial services technology. It operates through the Merchant and Financial segments. The Merchant segment offers commerce-enabling products and services including merchant acquiring and digital commerce and mobile payment services, and security and fraud protection, stored-value, and pay-by-bank solutions to companies of all sizes. The Financial segment provides products and services such as processing of customer loan and deposit accounts, digital payments, and card transactions to financial institutions and corporate and public sector clients. The company was founded by Leslie M. Muma and George D. Dalton on July 31, 1984 and is headquartered in Milwaukee, WI.

Fiserv, Inc.

Michael Burrys disclosed Fiserv position is drawing attention, with bullish traders framing the payments company as a contrarian value play and pointing to potential valuation read-through from reported interest in Global Payments. Others remain skeptical, citing Fiservs guidance cuts and unresolved execution concerns.

Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of therapeutics for metabolic dysfunction-associated steatohepatitis. The company was founded by Rebecca A. Taub, Frederick Bernard Craves, and Edward Chiang on March 10, 2000 and is headquartered in West Conshohocken, PA.

Madrigal Pharmaceuticals Inc

Madrigals quarterly results are drawing attention, with traders highlighting strong Rezdiffra growth and profitability. Reactions are mixed: some see the commercial momentum as encouraging, while others are concerned about the lack of guidance and spending, and frustrated that the shares faded after an initial rise.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantirs strong quarterly results and raised outlook were met with a selloff, as traders focused on the stocks rich valuation and slower growth in total contract value as possible signs that expectations are too high. Bulls point to rapid commercial AI adoption and stronger guidance, while others question whether bookings can sustain the growth priced into the shares.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is drawing attention ahead of its quarterly report, as traders weigh whether its AI and data-center outlook can counter concerns sparked by Intels weak forecast and the broader semiconductor selloff. Some see the pullback as setting up a rebound on strong guidance, while others fear that even a beat may not prevent more selling amid valuation and sector-wide concerns.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

The Body as Blueprint: A Recently Public Biotech Bets That Regrown Tissue Beats Replacement Parts

The Body as Blueprint: A Recently Public Biotech Bets That Regrown Tissue Beats Replacement Parts The Body as Blueprint: A Recently Public Biotech Bets That Regrown Tissue Beats Replacement Parts PR Newswire TAMPA, Fla., June 2, 2026 Issued on behalf of Conexeu Sciences Inc.A newly listed...

Organogenesis (ORGO) Projected to Post Earnings on Thursday

Organogenesis (NASDAQ:ORGO) will be releasing its Q1 2026 earnings after the market closes on Thursday, May 7. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-7-organogenesis-holdings-inc-stock...

Organogenesis (NASDAQ:ORGO) Trading Up 1.7% - Time to Buy?

Organogenesis (NASDAQ:ORGO) Shares Up 1.7% - What's Next...

ORGO Stock Rallies After Hours On Clearing Regulatory Pathway For Pain Relief Treatment 

Equity

Organogenesis is seeking approval for ReNu in knee osteoarthritis pain, a degenerative joint disease that is estimated to affect nearly 31.1 million Americans.


Organogenesis (NASDAQ:ORGO) Receives "Buy" Rating from BTIG Research

BTIG Research reissued a "buy" rating and issued a $8.00 price objective on shares of Organogenesis in a research report on Thursday...

Assenagon Asset Management S.A. Acquires 680,392 Shares of Organogenesis $ORGO

Assenagon Asset Management S.A. raised its stake in shares of Organogenesis (NASDAQ:ORGO - Free Report) by 14.0% during the fourth quarter, according to its most recent disclosure with the Securities...

Organogenesis $ORGO Shares Acquired by First Light Asset Management LLC

First Light Asset Management LLC lifted its stake in shares of Organogenesis (NASDAQ:ORGO - Free Report) by 10.6% during the 3rd quarter, according to the company in its most recent filing with the...

Insider Buying: Organogenesis (NASDAQ:ORGO) Director Buys 5,000 Shares of Stock

Organogenesis (NASDAQ:ORGO - Get Free Report) Director Arthur Leibowitz purchased 5,000 shares of the stock in a transaction on Monday, March 9th. The stock was acquired at an average cost of $2.68...

Michael Joseph Driscoll Buys 10,000 Shares of Organogenesis (NASDAQ:ORGO) Stock

Organogenesis (NASDAQ:ORGO - Get Free Report) Director Michael Joseph Driscoll purchased 10,000 shares of the business's stock in a transaction on Monday, March 9th. The shares were purchased at an...

Insider Buying: Organogenesis (NASDAQ:ORGO) Director Buys $13,400.00 in Stock

Organogenesis (NASDAQ:ORGO - Get Free Report) Director Arthur Leibowitz acquired 5,000 shares of the firm's stock in a transaction on Monday, March 9th. The shares were acquired at an average price...

Organogenesis Holdings, Inc. is a regenerative medical company, which engages in the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical and sports medicine markets. The company was founded in 1985 and is headquartered in Canton, MA.

Organogenesis Holdings Inc - Ordinary Shares - Class A

Neutral Sentiment

<ul class="summary-bullets"><li>ReNu is a cryopreserved, amniotic suspension allograft.</li><li>The company decided to initiate a rolling application for ReNu following the completion of a meeting with the FDA.</li><li>The treatment received FDA’s Regenerative Medicine Advanced Therapy (RMAT)-designation in 2021.</li></ul> Shares of Organogenesis Holdings Inc. (ORGO) jumped 22% in Monday’s extended trading hours after the company said that it met with the U.S. Food and Drug Administration (FDA), and now plans to initiate seeking approval for its experimental treatment ReNu before the end of December.The company is seeking approval for ReNu in the treatment of knee osteoarthritis pain, a degenerative joint disease that is estimated to affect nearly 31.1 million Americans.ReNu is a cryopreserved, amniotic suspension allograft. It provides anti-inflammatory, growth factor, and cellular components, offering a non-surgical alternative to reduce inflammation, alleviate pain, and enhance joint function. The treatment received FDA’s Regenerative Medicine Advanced Therapy (RMAT)-designation in 2021.<h2 class="st-heading-2">ReNu Application</h2>The company decided to initiate a rolling application for ReNu following the completion of a meeting with the FDA.“We are excited about the outcome of our FDA meeting and reaching this important milestone in the ReNu program. We are pleased the ReNu clinical development program consisting of two large Phase 3 randomized controlled trials (RCT), extensive commercial history and Regenerative Medicine Advanced Therapy (RMAT)-designation is appropriate for BLA submission,” said Patrick Bilbo, Chief Operating Officer of Organogenesis.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around ORGO stock stayed within the ‘neutral’ territory while message volume remained at ‘normal’ levels.According to data from Koyfin, the sole analyst covering ORGO rated it ‘Buy’ with a $8 price target that implies a potential upside of about 257% from current trading levels.<a href="https://stocktwits.com/symbol/ORGO">ORGO stock</a> has fallen 42% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/neurocrine-soleno-deal-garners-wall-street-praise/cZJ4wmmRIYV">Neurocrine-Soleno Deal Garners Wall Street Praise — Analyst Applauds Business Development Acumen</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Organogenesis is seeking approval for ReNu in knee osteoarthritis pain, a degenerative joint disease that is estimated to affect nearly 31.1 million Americans.

iShares Russell 2000 ETF

Vanguard Total Stock Market ETF

Up more than 3%

Flat to up 3%

Flat to down 3%

Down more than 3%

What’s your expected total return for the S&amp;P 500 ($SPY) in November?

Stocktwits

What’s your expected total return for the S&P 500 (

Current Price	$0.7555
Prev Close	$0.7681
Open	$0.78
Dividend Yield	0.00%
50-Day Moving Average	$1.33
Beta	1.82
Avg. Volume	941,870.30
PE Ratio	-0.91

52-Week High	$7.08
52-Week Low	$0.73
Market Capitalization	$97.21M
EPS (Annual)	$0.1537
Price to Book	0.66
Revenue Per Employee	$660,619.44

Feed

News

Sentiment

Earnings

Fundamentals

Info

ORGO Fundamentals